Want to see PRCT full AI Analyst Report?
PRCT Stock Chart & Stats
$16.69
$1.00(5.99%)
At close: 4:00 PM EDT
$16.69
$1.00(5.99%)
Day’s Range― - ―
52-Week Range$16.67 - $51.18
Previous Close$18
Volume1.34M
Average Volume (3M)1.71M
Market Cap
$1.06B
Enterprise Value$1.25K
Total Cash (Recent Filing)$245.64M
Total Debt (Recent Filing)$51.66M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Aug 04, 2026EPS Estimate
-0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding56,918,842
10 Day Avg. Volume1,591,226
30 Day Avg. Volume1,706,467
Financial Highlights & Ratios
PEG Ratio10.67
Price to Book (P/B)4.78
Price to Sales (P/S)5.67
P/FCF Ratio-29.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$27.83Price Target Upside66.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.54
Revenue Forecast (FY)$397.43M
Bulls Say, Bears Say
Bulls Say
Revenue And Procedure Adoption MomentumSustained double‑digit revenue growth and strong procedure volume indicate expanding clinical adoption and an increasing installed base. Durable adoption by hospitals and urologists supports recurring consumable and service revenue, improving unit economics as procedures scale over the next several quarters.
High And Improving Gross MarginsGross margin around 65% reflects favorable product mix, pricing power (system ASPs and handpiece ASP increases) and operational leverage. Durable high margins create a strong profit pool for scaling the business and support future investment in commercialization without eroding unit economics.
Solid Liquidity And Modest LeverageA sizable cash reserve combined with low leverage provides runway to fund commercial expansion, international launches, and the WATER IV trial. This reduces near‑term refinancing risk and gives management flexibility to invest in adoption and absorb temporary execution delays.
Bears Say
Consistent Negative Operating And Free Cash FlowPersistent negative operating and free cash flows indicate the business still requires external funding or uses cash reserves to sustain growth. Even with improving trends, continued cash burn risks dilution or constrained investment if revenue or margin improvements slow versus plan.
Substantial Operating And Net LossesLarge recurring GAAP losses depress returns on equity and erode the equity base, limiting internal capital generation. Long‑term profitability depends on continued scale and cost discipline; failure to convert top‑line growth into sustained operating profits raises structural risk for investors.
Rising Operating Expenses And Execution Risk From RealignmentHigher operating spend to fund commercial expansion and trials increases the breakeven threshold and makes results sensitive to execution. Organizational changes that disrupted near‑term procedures risk delaying benefits from investments and could push margin inflection points further out if ramping underperforms.
PROCEPT BioRobotics News
PRCT FAQ
What was Procept Biorobotics Corp.’s price range in the past 12 months?
Procept Biorobotics Corp. lowest stock price was $16.66 and its highest was $51.18 in the past 12 months.
What is Procept Biorobotics Corp.’s market cap?
Procept Biorobotics Corp.’s market cap is $1.06B.
When is Procept Biorobotics Corp.’s upcoming earnings report date?
Procept Biorobotics Corp.’s upcoming earnings report date is Aug 04, 2026 which is tomorrow.
How were Procept Biorobotics Corp.’s earnings last quarter?
Procept Biorobotics Corp. released its earnings results on Apr 29, 2026. The company reported -$0.56 earnings per share for the quarter, beating the consensus estimate of -$0.563 by $0.003.
Is Procept Biorobotics Corp. overvalued?
According to Wall Street analysts Procept Biorobotics Corp.’s price is currently Undervalued.
Does Procept Biorobotics Corp. pay dividends?
Procept Biorobotics Corp. does not currently pay dividends.
What is Procept Biorobotics Corp.’s EPS estimate?
Procept Biorobotics Corp.’s EPS estimate is -0.46.
How many shares outstanding does Procept Biorobotics Corp. have?
Procept Biorobotics Corp. has 56,918,842 shares outstanding.
What happened to Procept Biorobotics Corp.’s price movement after its last earnings report?
Procept Biorobotics Corp. reported an EPS of -$0.56 in its last earnings report, beating expectations of -$0.563. Following the earnings report the stock price went up 10.732%.
Which hedge fund is a major shareholder of Procept Biorobotics Corp.?
Currently, no hedge funds are holding shares in PRCT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PROCEPT BioRobotics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$27.83 (66.77% Upside)
$27.83 (66.77% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $18.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-71.53%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.22%
Trailing 12-Months
Company Description
Procept Biorobotics Corp.
PROCEPT BioRobotics Corporation specializes in pioneering surgical robotic technologies, offering innovative solutions within the field of urology. Its flagship product is the AquaBeam Robotic System, a sophisticated, image-guided surgical robot designed for minimally invasive urological procedures. This system primarily facilitates Aquablation therapy, which the company also devised, to alleviate lower urinary tract symptoms in male patients diagnosed with benign prostatic hyperplasia (BPH). As of year-end 2021, PROCEPT BioRobotics had successfully deployed 130 AquaBeam Robotic Systems across the globe, with a significant majority—78 units—located in the United States. Founded in 2007, the corporation maintains its headquarters in Redwood City, California.
PRCT Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive operational and commercial trajectory: robust top‑line growth (20% revenue; ~30% procedure growth), margin expansion to management targets (65% gross margin), pricing discipline and meaningful clinical/regulatory wins (EAU guideline upgrade, FDA clearance). These positives are balanced against higher operating expenses, larger GAAP and adjusted EBITDA losses in Q1, tariff headwinds and short‑term disruption from a commercial realignment that push some benefits into the back half of 2026. Management reaffirmed full‑year guidance while taking a prudent near‑term stance, expecting improved leverage and positive EBITDA in Q4.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$27.83
▲(66.77% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.00% Insiders
22.48% Mutual Funds
5.82% Other Institutional Investors
51.31% Public Companies and
Individual Investors